Da hat sich in der Zwischenzeit etwas getan:
Die englischsprachige Wikipedia berichtet:
################################################
A
Phase III clinical trial was scheduled to begin in the first half of 2007, but was delayed until August 2007. On August 30, Palatin announced that the
U.S. Food and Drug Administration had expressed serious concerns regarding the
risk/benefit ratio of bremelanotide with regards to the side effect of increased blood pressure. The FDA stated that they would consider alternate uses for bremelanotide, including as a treatment for individuals who do not respond to more established ED treatments. However, On May 13, 2008, Palatin Technologies announced it had "discontinued development of Bremelanotide for the treatment of male and female sexual dysfunction" while concurrently announcing plans to develop it as a treatment for hemorrhagic shock instead.
[5] The company additionally announced intentions to focus its attention on another compound, PL-6983, that causes lower blood pressure in
animal models.
[6] Palatin has since re-initiated Bremelanotide studies for ED and FSD using a subcutaneous delivery method. On August 12, 2009, the company announced that in a double-blind study of 54 volunteers bremelanotide failed to evoke the hypertensive side effects seen with the nasal delivery system used in prior studies, concluding that "variability of uptake" inherent in intranasal administration of the drug resulted in "increases in blood pressure and gastrointestinal events...primarily related to high plasma levels in [only] a subset of patients" and that subcutaneous administration of the drug circumvented the potential for this side effect. It is now in discussions with the FDA to resume Human Phase 2 studies utilizing subcutaneous administratration.
################################################
Somit geht das ganze wieder von vorne los:
- Phase IIa (Pharmakokinetik - also wie das Mittel aufgenommen wird)
- Phase II (Dosierung)
- Phase III (Wirksamkeit)
Da jede Studie mindestens 1-2 Jahre dauern wird, wird frühestens 2017 das Mittel von der FDA (Zulassungsbehörde für die USA) zugelassen sein. Meist wartet die EMEA (Zulassungsbehörde für die EU) noch ein Jahr ab und läßt dann zu.
Aber mal ehrlich: Wer setzt sich schon gerne vor dem Sex eine Spritze?